INTRODUCTION
Pulmonary surfactant is a complex of surface-active lipids, especially dipalmitoylphosphatidylcholine (DPPC), and at least four specific surfactant proteins, SP-A, SP-B, SP-C and SP-D. It is synthesized in alveolar type II cells and assembled into lamellar bodies. DPPC, SP-B and SP-C are secreted together in lamellar bodies while at least one part of synthesized SP-A is secreted independently. From its site of storage in lamellar bodies, pulmonary surfactant reaches its site of action at the alveolar airliquid interfaces through a series of transformations including swelling of secreted lamellar bodies to tubular myelin. A major function of surfactant is to reduce surface tension, thus preventing the alveoli to collapse during end-expiration. The two hydrophobic proteins SP-B and SP-C are critical for the adsorption and spreading of the surfactant film at the air-liquid interface. Although accomplished in cooperation with surfactant-associated proteins, it is the lipids, especially DPPC, that are ultimately responsible for surface tension reduction to low values during expiration. The main function of the hydrophilic surfactant proteins SP-A and SP-D is to participate in pulmonary host defence.
The secretion and recycling of surfactant are regulated by feedback mechanisms, presumably via several classes of receptors identified both on type II cells and macrophages.
1 DPPC, with a biological half-life time of about 10-12 hours is taken up and catabolized by macrophages or is taken up by type II cells to be catabolized or recycled back into lamellar bodies. The biological half-life values for different surfactant proteins range from about 6 to 28 hours and vary with species. The regulation of surfactant homeostasis and the relative importance of type II cells and macrophages to the catabolism of surfactant components remains to be characterized.
Respiratory Distress Syndrome
Surfactant deficiency in preterm babies is the cause of respiratory distress syndrome (RDS). Impaired surfactant is also a central feature in the pathophysiology of many types of acute lung injury. Treatment of RDS with exogenous surfactant instilled into the airways is now in general use and several surfactant preparations are commercially available. The most satisfactory results have been obtained with preparations derived from animal lungs. Common components in these preparations are phospholipids, mainly DPPC, and the hydrophobic surfactant proteins SP-B and SP-C. Both proteins accelerate film formation at the air-liquid interface, probably by different mechanisms. The fundamental roles of both endogenous SP-B and SP-C in pulmonary surfactant have been verified by experimental and clinical observations. Gene targeting experiments have revealed that both SP-B and SP-C knockout mice are unable to establish normal breathing. 2, 3 Infants with SP-B deficiency develop progressive, lethal respiratory failure in the neonatal period while patients with SP-C deficiency will develop progressive lung fibrosis. 4 
Natural Surfactant Preparations
Surfactant preparations derived from animal lungs are expensive with a limited supply, and they pose a danger of propagating infectious material. Thus, there is a need for synthetic surfactant substitutes, which can be produced in large quantities at a reasonable cost. In acute lung injury, which can arise in association with meconium aspiration, sepsis, trauma, diffuse pneumonia and circulatory shock, surfactant is not lacking but plasma proteins leaking into the airspaces inhibit its activity. For successful treatment of these lung diseases, it is desirable that the instilled surfactant may resist inactivation by different components.
Synthetic Surfactant Preparations
Development of clinically active synthetic surfactants has turned out to be complicated. SP-B is too big and structurally complex to be synthesized by organic chemical methods and expression of functionally active recombinant SP-B has not been reported. SP-C is extremely hydrophobic and especially in pure form structurally unstable. 5 Attempts to identify analogues of the two hydrophobic surfactant proteins SP-B and SP-C in order to formulate a synthetic surfactant preparation are going on in several laboratories. These efforts stem from the fact that SP-B and SP-C appear to be essential for optimal function of natural surfactant preparations used for treatment of RDS in premature infants. SP-B is a 17.4 kDa homodimer of two 79-residue polypeptide chains containing several amphipathic a-helices, and probably interacts with the superficial parts of phospholipid membranes.
6 SP-C is a 4.2 kDa lipopeptide with an a-helix that spans a phospholipid bilayer, 7 or can interact in a tilted orientation with a phospholipid monolayer. 8 The analogues presented so far include KL 4 , a 21-residue peptide. According to Cochrane and Revak, 9 the peptide was designed based on repeated sequence motifs found in SP-B. Airway instillation of KL 4 surfactant reportedly improves lung function in animal models of neonatal surfactant deficiency 9, 10 and meconium aspiration syndrome 11 as well as in babies with RDS. 12 Several analogues based on the SP-C structure have been described. Synthetic SP-C analogues with the native poly-Val sequence are capable of forming effective surfactants. 13 Surfactant based on recombinant SP-C (rSP-C), in which the native poly-Val sequence is present, improves lung function in premature newborn rabbits and lambs 14, 15 as well as in animal models of acute lung injury. 16, 17 However, treatment with rSP-C surfactant in patients with acute RDS did not improve survival but had a benefit in gas exchange during the 24-hour treatment period. 18 In our experience, synthetic SP-C containing a poly-Val sequence exhibits low surface activity in vitro, mainly because this peptide does not fold into the helical conformation shown by SP-C isolated from lung tissue but has a strong tendency to form aggregates with the peptide in a b-sheet conformation. 19 In order to overcome the difficulties, a poly-Val-poly-Leu-substituted SP-C analogue (SP-C(Leu)) was synthesized and found to be virtually identical to native SP-C in terms of secondary structure and in vitro surface spreading properties. 20 SP-C(Leu)/lipid mixtures, however, only show a modest effect on dynamic lung compliance in premature rabbit foetuses. This was correlated with the fact that SP-C(Leu) oligomerizes into dimers, tetramers, hexamers and probably also higher order oligomers, which makes it difficult to suspend SP-C(Leu)/lipid mixtures at concentrations higher than 20 mg/ml. 20 Moreover, a poly-Leu SP-C analogue was synthesized by Takei et al. 21 and found to be active in vivo. The problem with peptide oligomerization was circumvented by synthesizing a modified peptide, SP-C(LKS), containing three lysines incorporated in the SP-C(Leu) sequence in such a way that they cover the helix circumference and reduce peptide-peptide interactions. 22 This peptide, SP-C(LKS), combined with lipids exhibits rapid adsorption and spreading, 22 and can be suspended at 80 mg/ml. However, instillation of this preparation does not significantly improve lung compliance of premature rabbit foetuses (unpublished data). The reason for this is not known but it is possible that introduction of positively charged Lys residues in the middle and C-terminal regions interfere with the strong SP-C dipole moment (from the intrinsic helix dipole and from the positively charged N-terminal residues) and/or influence the peptide/membrane interactions. The problems with peptide oligomerization and interference with the dipole moments were circumvented by synthesizing an SP-C analogue (SP-C33) with one positive charge in the N-terminal part of the a-helical chain. SP-C33/lipid mixtures can be suspended and administered to premature rabbits at a concentration of 80 mg/ml. The synthetic surfactant preparation increases lung compliance in preterm rabbit foetuses to levels similar to those obtained with commercially available modified natural surfactant preparations currently used for treatment of clinical RDS. 23 However, the activity is dependent on the lipid composition. Administration of surfactants at high concentration is likely to be important for optimal treatment effects, as evidenced by the reduced spreading observed at low phospholipid concentrations in natural surfactant preparations. 24 Addition of 2% (w/w) of the lipid vesicle crosslinking peptide polymyxin B to the surfactant preparation increased the resistance of pulmonary surfactants to inactivation as well as it improved their surface properties. 25 Histological examination shows that animals treated with SP-C33/lipid mixtures have no or only mild airway epithelial damages, comparable to the effects of treatment with modified natural surfactants. However, end-expiratory lung gas volumes are significantly larger in animals treated with Poractant Alfa (Curosurf s , DEY Laboratories, Napa, CA) than in those receiving SP-C33/lipid mixtures and significantly larger in animals treated with the synthetic surfactant and ventilated with positive endexpiratory pressure (PEEP) than in those ventilated without PEEP. 23 The combination of relatively large tidal volumes and low end-expiratory lung gas volumes in animals receiving SP-C33/lipid mixtures indicates alveolar instability, which at least under the present experimental conditions can be compensated for by application of PEEP. Further studies are required to find out whether treatment effects on lung gas volumes can be improved by adding SP-B (or some analogue of SP-B) to the synthetic surfactant, or by modifying the lipid composition.
